Good news?, page-25

Whilst access may become easier, I'm not sure perceived advantages will outweigh the likely disadvantages. Confusion reigns.

Correct me if I am wrong, but the products currently 'packaged' do not target a particular medical issue the punter is trying to solve i.e. one size fits all. That doesn't work.

I also don't recall any vendors discussing terpene profiles at any length. The known players and assumed brains trusts in Nimbin no different. There's a long long way to go (both here and internationally) before we see weed become a medical staple.

Just my 2 cents worth and really not much connection to the success or failures of CGB.